RNAi-mediated inhibition of ocular targets
US7592324B2 · kind B2 · utility
15Cited by
3References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 1, 2006 |
| Grant date | Sep 22, 2009 |
| Priority date | — |
| Expiry date | Jul 16, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/53
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.